Ovoca Bio Regulatory News (OVB)

Ovoca Bio plc

("Ovoca" or the "Company")

Notice of Extraordinary General Meeting

Dublin, Ireland, 25 January 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women's health, announces that an Extraordinary General Meeting of the Company will be held at 17 Pembroke Street Upper, Dublin 2, Ireland on 16 February 2021 at 11.00 am (the "EGM").

The EGM is being convened to seek the approval of shareholders to certain resolutions which are intended to facilitate the migration of the Company's ordinary shares from the CREST System to the central securities depository ("CSD") system operated by Euroclear Bank SA/NV, an international CSD incorporated in Belgium, following the withdrawal of the UK from the EU, and to make subsequent changes to the Company's Articles of Association (the "Resolutions").

The approval of the Resolutions is necessary to ensure the continuation of electronic settlement of the Company's ordinary shares when traded on Euronext Growth and AIM and to remain eligible for continued admission to trading on those exchanges, which the Board believes is essential to the interests of the Company and its shareholders.

The circular, which includes the notice of the EGM, (the "Circular") and a Form of Proxy will be posted to shareholders today. The Board strongly urges shareholders to review the contents of the Circular in their entirety, including the documents referred to therein, and to consider the Board's recommendation that shareholders vote in favour of the Resolutions.

The Circular, the Form of Proxy and copies of the documents referred to in the Circular are available to view on the Company's website, www.ovocabio.com, and will be available for inspection during normal working hours on any business day from the date of this announcement until the EGM at the Registered Office of the Company.

COVID-19 Guidelines

The well-being of our Shareholders and our people is a primary concern for the Directors. We are closely monitoring the COVID-19 situation and any advice by the Government of Ireland in relation to the pandemic. We will take all recommendations and applicable law into account in the conduct of the EGM. However, the Board is discouraging attendance at the EGM in person and we would therefore encourage Shareholders to submit their Form of Proxy to ensure they can vote and be represented at the EGM.

The Company continues to monitor the impact of COVID-19 and any relevant updates regarding the EGM, including any changes to the arrangements outlined in the Circular, will be announced via a Regulatory Information Service and will be available on www.ovocabio.com.

It will be possible to listen to the proceedings of the EGM remotely by utilising a teleconference facility provided by the Company for this purpose. Shareholders will not be able to use this facility to vote, ask questions or table resolutions. To join the teleconference facility, and receive dial-in access numbers and participant passcodes, please register on the Company website at www.ovocabio.com before 11am on 12 February 2021.

All shareholders will be able to submit questions in advance of the EGM in writing by email to the Company Secretary at info@ovocabio.com to be received no later than 11am on 12 February 2021. All correspondence should include sufficient information to identify the shareholder on the Register of Members.

Terms used but not defined in this announcement have the same meaning as set out in the Circular.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.